Who
Jeffrey Stuart Peters
Senior VP, GC, and Secretary
Company insider
Files Form 4 as: Senior VP, GC, and Secretary, MacroGenics.
In numbers
- Trades disclosed
- 78
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $3.6M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 31 May 2017
- Last trade
- 19 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Aug 2026filed 20 Aug 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Sold | $129K31,105 at $4.15 | filing |
| 19 Aug 2026filed 20 Aug 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Sold | $129K31,105 at $4.15 | filing |
| 15 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —13,332 | filing |
| 15 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code F | $8,8015,147 at $1.71 | filing |
| 15 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,332 at $0.00 | filing |
| 15 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,332 at $0.00 | filing |
| 15 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —13,332 | filing |
| 15 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code F | $8,8015,147 at $1.71 | filing |
| 12 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 8 Feb 2026filed 10 Feb 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —8,999 | filing |
| 8 Feb 2026filed 10 Feb 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,999 at $0.00 | filing |
| 8 Feb 2026filed 10 Feb 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code F | $6,2883,474 at $1.81 | filing |
| 8 Feb 2026filed 10 Feb 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,999 at $0.00 | filing |
| 8 Feb 2026filed 10 Feb 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —8,999 | filing |
| 8 Feb 2026filed 10 Feb 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code F | $6,2883,474 at $1.81 | filing |
| 7 Feb 2026filed 10 Feb 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —6,001 | filing |
| 7 Feb 2026filed 10 Feb 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code F | $4,1942,317 at $1.81 | filing |
News
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHNMGNX · manilatimes.net · 23 Oct 2026MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid TumorsMGNX · manilatimes.net · 15 Oct 2026Head-To-Head Contrast: Zenas BioPharma (NASDAQ:ZBIO) and MacroGenics (NASDAQ:MGNX)MGNX · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Jeffrey Stuart Peters; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.